Investigation on effect of basalin coated silver nanoparticles as antioxidant for alleviating peripheral neuropathy in mice treated with oxaliplatin

Gao, Lei; Zheng, Yumei; Zhao, Chengbo; Teng, Hongtao

doi:10.1016/j.jphotobiol.2017.10.003

Cited by 5 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This evidence agrees with the hypothesis that antineoplastic agents can increase pain modulators and free radical production, to whom mammalian nerves seem to be more susceptible [20,21]. In this view, the degradation of non-functional oxidized proteins is essential for the maintenance of antioxidant defense machinery [22][23][24] that seems compromised in OXAIN.…”

Section: Introductionsupporting

confidence: 88%

The active second-generation proteasome inhibitor oprozomib reverts the oxaliplatin-induced neuropathy symptoms

Caputi

Mannelli

Rullo

et al. 2020

Biochemical Pharmacology

View full text Add to dashboard Cite

Oxaliplatin-induced neuropathy (OXAIN) is a major adverse effect of this antineoplastic drug, widely used in the treatment of colorectal cancer. Although its molecular mechanisms remain poorly understood, recent evidence suggest that maladaptive neuroplasticity and oxidative stress may participate to the development of this neuropathy. Given the role played on protein remodeling by ubiquitin-proteasome system (UPS) in response to oxidative stress and in neuropathic pain, we investigated whether oxaliplatin might cause alterations in the UPSmediated degradation pathway, in order to identify new pharmacological tools useful in OXAIN. In a rat model of OXAIN (2.4 mg kg − 1 i.p., daily for 10 days), a significant increase in chymotrypsin-(β5) like activity of the constitutive proteasome 26S was observed in the thalamus (TH) and somatosensory cortex (SSCx). In addition, the selective up-regulation of β5 and LMP7 (β5i) subunit gene expression was assessed in the SSCx. Furthermore, this study revealed that oprozomib, a selective β5 subunit proteasome inhibitor, is able to normalize the spinal prodynorphin gene expression upregulation induced by oxaliplatin, as well as to revert mechanical allodynia and thermal hyperalgesia observed in oxaliplatin-treated rats. These results underline the relevant role of UPS in the OXAIN and suggest new pharmacological targets to counteract this severe adverse effect.This preclinical study reveals the involvement of the proteasome in the oxaliplatin-induced neuropathy and adds useful information to better understand the molecular mechanism underlying this pain condition. Moreover, although further evidence is required, these findings suggest that oprozomib could be a therapeutic option to counteract chemotherapy-induced neuropathy.

show abstract

Section: Introductionsupporting

confidence: 88%

The active second-generation proteasome inhibitor oprozomib reverts the oxaliplatin-induced neuropathy symptoms

Caputi

Mannelli

Rullo

et al. 2020

Biochemical Pharmacology

View full text Add to dashboard Cite

show abstract

“…Some new perspectives of drug preparation and application are being investigated. Therefore, basalin-coated silver nanoparticles were developed and applied as a potent antioxidant for the amelioration of oxaliplatin-induced peripheral neuropathy in mice [ 92 ]. They were able to significantly perform the chelation of aluminum and consequently ameliorate neuropathic pain in mice.…”

Section: Antioxidants In the Treatment Of Platinum-based Chemothermentioning

confidence: 99%

Antioxidant Supplementation in the Treatment of Neurotoxicity Induced by Platinum-Based Chemotherapeutics—A Review

Stanković

Selaković

Mihailović

et al. 2020

IJMS

View full text Add to dashboard Cite

Cancer represents one of the most pernicious public health problems with a high mortality rate among patients worldwide. Chemotherapy is one of the major therapeutic approaches for the treatment of various malignancies. Platinum-based drugs (cisplatin, oxaliplatin, carboplatin, etc.) are highly effective chemotherapeutic drugs used for the treatment of several types of malignancies, but their application and dosage are limited by their toxic effects on various systems, including neurotoxicity. Simultaneously, researchers have tried to improve the survival rate and quality of life of cancer patients and decrease the toxicity of platinum-containing drugs by combining them with non-chemotherapy-based drugs, dietary supplements and/or antioxidants. Additionally, recent studies have shown that the root cause for the many side effects of platinum chemotherapeutics involves the production of reactive oxygen species (ROS) in naive cells. Therefore, suppression of ROS generation and their inactivation with antioxidants represents an appropriate approach for platinum drug-induced toxicities. The aim of this paper is to present an updated review of the protective effects of different antioxidant agents (vitamins, dietary antioxidants and supplements, medicaments, medicinal plants and their bioactive compounds) against the neurotoxicity induced by platinum-based chemotherapeutics. This review highlights the high potential of plant antioxidants as adjuvant strategies in chemotherapy with platinum drugs.

show abstract

“…Some CeO 2 -based therapeutic agents [e.g., CeO 2 -decorated MSNs ( Wu H. et al, 2018 ), CeO 2 -integrated microneedle patches ( Yuan et al, 2021 )] and theragnostic agents (e.g., Fe 3 O 4 /CeO 2 core–shell NPs) ( Wu Y. et al, 2018 ), Fe 3 O 4 /CeO 2 -coated layered double hydroxide (LDH) nanocomposites ( Liu et al, 2019 ), and Fe 3 O 4 /CeO 2 chitosan nanococktails ( Wu et al, 2021 )] have been developed to scavenge ROS for the treatment and/or diagnosis of ROS-related inflammatory diseases. Moreover, Gao et al synthesized basalin-coated silver (Ag) NPs in aqueous medium using silver nitrate, which alleviated neuropathic pain of OXA-treated mice by decreasing the aluminum (Al) levels in the DRG via chelation ( Gao et al, 2017 ). Therefore, versatile inorganic NPs could be designed to eliminate the level of ROS or Al for synergistic treatment of PIPN.…”

Section: Nanotechnology-based Strategies To Overcome Platinum-induced Peripheral Neuropathymentioning

confidence: 99%

Platinum-Induced Peripheral Neuropathy (PIPN): ROS-Related Mechanism, Therapeutic Agents, and Nanosystems

Jiang

Teng

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

Platinum (Pt) drugs (e.g., oxaliplatin, cisplatin) are applied in the clinic worldwide for the treatment of various cancers. However, platinum-induced peripheral neuropathy (PIPN) caused by the accumulation of Pt in the peripheral nervous system limits the clinical application, whose prevention and treatment are still a huge challenge. To date, Pt-induced reactive oxygen species (ROS) generation has been studied as one of the primary mechanisms of PIPN, whose downregulation would be feasible to relieve PIPN. This review will discuss ROS-related PIPN mechanisms including Pt accumulation in the dorsal root ganglia (DRG), ROS generation, and cellular regulation. Based on them, some antioxidant therapeutic drugs will be summarized in detail to alleviate the Pt-induced ROS overproduction. More importantly, we focus on the cutting-edge nanotechnology in view of ROS-related PIPN mechanisms and will discuss the rational fabrication of tailor-made nanosystems for efficiently preventing and treating PIPN. Last, the future prospects and potential breakthroughs of these anti-ROS agents and nanosystems will be briefly discussed.

show abstract

Investigation on effect of basalin coated silver nanoparticles as antioxidant for alleviating peripheral neuropathy in mice treated with oxaliplatin

Cited by 5 publications

References 21 publications

The active second-generation proteasome inhibitor oprozomib reverts the oxaliplatin-induced neuropathy symptoms

The active second-generation proteasome inhibitor oprozomib reverts the oxaliplatin-induced neuropathy symptoms

Antioxidant Supplementation in the Treatment of Neurotoxicity Induced by Platinum-Based Chemotherapeutics—A Review

Platinum-Induced Peripheral Neuropathy (PIPN): ROS-Related Mechanism, Therapeutic Agents, and Nanosystems

Contact Info

Product

Resources

About